NIKKEI 225
37,552.16 +113.55 (+0.30%) HANG SENG
16,828.93 +317.24 (+1.92%) CRUDE OIL
83.40 +1.50 (+1.83%) GOLD FUTURES
2,338.20 -8.20 (-0.35%) DOW
38,486.11 +246.13 (+0.64%) Bitcoin GBP
53,614.77 +327.26 (+0.61%)
Boston Scientific Corporation (0HOY.L)
| Previous close | 68.52 |
| Open | 68.32 |
| Bid | 0.00 x 0 |
| Ask | 0.00 x 0 |
| Day's range | 68.11 - 68.85 |
| 52-week range | 47.37 - 68.85 |
| Volume | |
| Avg. volume | 26,833 |
| Market cap | 953.348M |
| Beta (5Y monthly) | 0.79 |
| PE ratio (TTM) | 1.30 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Zacks
What's in Store for These 4 Medical Products Stocks in Q1 Earnings?
Medical Products companies' quarterly results are likely to reflect a year-over-year decline in earnings. Let's see how BSX, TMO, ALGN and ICLR fare this time.
- Zacks
Unveiling Boston Scientific (BSX) Q1 Outlook: Wall Street Estimates for Key Metrics
Beyond analysts' top -and-bottom-line estimates for Boston Scientific (BSX), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2024.
- Benzinga
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
On Wednesday, Boston Scientific Corporation (NYSE:BSX) said it recalled Obsidio Embolic by issuing a correction. The FDA has identified this as a Class I recall, the most severe type of recall. An investigation determined that delivery of Obsidio Embolic using the aliquot technique, a commonly used delivery method in embolization procedures, for lower gastrointestinal (GI) bleeding embolization, implies a high risk of bowel ischemia. The most serious and the most common adverse health consequenc
